We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL

Law360 (March 1, 2018, 9:02 PM EST) -- Valeant Pharmaceuticals International Inc. on Wednesday said it will pay more than $58 million to end pay-for-delay litigation in Massachusetts federal court alleging subsidiary Medicis Pharmaceutical Corp. illegally kept a generic for the acne medication Solodyn off the market.

Valeant will pay a combined $58 million, pending court clearance, to classes of end-payor and direct-purchaser plaintiffs, according to a U.S. Securities and Exchange Commission filing. The drugmaker also said it settled with the remaining plaintiffs, Walgreen Co., CVS Pharmacy Inc. and Rite-Aid Corp., for an undisclosed...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.